Association of atrial high-rate episodes daily burden with the risk of cardiovascular death, heart failure hospitalization, and stroke.

Heart RhythmMar 4, 2026 (epub)
Clinical ResearchCardiology

Giovanni Luca Botto, Ennio C L Pisanò, Antonio Rapacciuolo et al.

✦ AI-curated · Sources linked

In 30 seconds

This analysis of patients with sinus node dysfunction and implanted dual-chamber pacemakers or defibrillators from the multicentre B3 randomized trial assessed whether device-detected atrial high-rate episode (AHRE) burden was associated with cardiovascular outcomes over 3 years. Among patients without prior atrial fibrillation (AF), a daily AHRE burden of at least 6 minutes was associated with the composite of cardiovascular death, worsening heart failure hospitalization, and stroke or transient ischemic attack (hazard ratio 4.9; 95% CI, 2.19-10.91). No significant association was found among patients with prior AF.

Key findings

  • AHRE burden ≥6 minutes occurred in 52.5% of patients; 47.1% of those patients had no prior AF.
  • Among patients without prior AF, AHRE burden ≥6 minutes was associated with the primary composite outcome (HR 4.9; 95% CI, 2.19-10.91; P < .001).
  • In patients without prior AF, associations were reported for cardiovascular death (P = .033), worsening heart failure hospitalization (P < .001), and progression to long-lasting AF (P < .001), but not stroke/TIA (P = .34).
  • Among patients with prior AF, the primary outcome was not significantly associated with AHRE burden ≥6 minutes (HR 0.83; 95% CI, 0.37-1.87; P = .65).

Why it matters

Device-detected AHREs may identify patients without a history of AF who have greater risk of major cardiovascular events, particularly heart failure hospitalization and cardiovascular death. The differing findings by prior AF status suggest that AHRE burden should be interpreted in the context of AF history; the results do not establish that AHREs cause these outcomes.

What to keep in mind

The analysis was based on patients with sinus node dysfunction and implanted devices, so its findings may not apply to other populations. The abstract reports 65 primary events, limiting the number of outcome events available for analysis.

Source

Published in Heart Rhythm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.